ArticleNature communications2014
Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 117 citations in OpenAlex.
- Chemokine-defined macrophage niches establish spatial organization of tumor immunity.Nature immunology · 2026Article
- Article
- Role of conventional dendritic cells in schistosomiasis-induced pulmonary hypertension.Clinical science (London, England : 1979) · 2025Article
- Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells.Vaccines · 2025Article
- Striking a balance: new perspectives on homeostatic dendritic cell maturation.Nature reviews. Immunology · 2025Review
- Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment.Cytotherapy · 2024Article
- Natural antibodies drive type 2 immunity in response to damage-associated molecular patterns.JCI insight · 2024Article
- Lung cDC1 and cDC2 dendritic cells priming naive CD8Cell reports · 2023Article
- The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.NPJ vaccines · 2023Article
- Channeling antigens to CD8Science (New York, N.Y.) · 2023Article
- Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Frontiers in immunology · 2023Review
- Therapeutic applications of toll-like receptors (TLRs) agonists in AML.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds.Vaccines · 2022Review
- Natural Antibodies Alert the Adaptive Immune System of the Presence of Transformed Cells in Early Tumorigenesis.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Article
- Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.NPJ vaccines · 2022Article
- Trafficking and retention of protein antigens across systems and immune cell types.Cellular and molecular life sciences : CMLS · 2022Review
- Review
- Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity.Molecular therapy oncolytics · 2022Article
- Immune escape mechanisms of severe fever with thrombocytopenia syndrome virus.Frontiers in immunology · 2022Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Dendritic cells (DCs) are required for the induction of cytotoxic T cells (CTL). In most tissues, including the lung, the resident DCs fall into two types expressing the integrin markers CD103 and CD11b. The current supposition is that DC function is predetermined by lineage, designating the CD103(+) DC as the major cross-presenting DC able to induce CTL. Here we show that Poly I:C (TLR3 agonist) or R848 (TLR7 agonist) do not activate all endogenous DCs. CD11b(+) DCs can orchestrate a CTL response in vivo in the presence of a TLR7 agonist but not a TLR3 agonist, whereas CD103(+) DCs require ligation of TLR3 for this purpose. This selectivity does not extend to antigen cross-presentation for T-cell proliferation but is required for induction of cytotoxicity. Thus, we demonstrate that the ability of DCs to induce functional CTLs is specific to the nature of the pathogen-associated molecular pattern (PAMP) encountered by endogenous DC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.